Hympavzi, made by Pfizer, is the first antitissue-factor pathway inhibitor to be approved for the blood-clotting disorder, as ...

The Food and Drug Administration on Friday approved a new kind of medicine for hemophilia, clearing Pfizer’s Hympavzi for people ... to receive Hympavzi, the FDA said. The drug is taken once ...

First, the Big Pharma scored an FDA approval for its hemophilia B gene therapy Beqvez. But of greater concern for Centessa was the approval granted last month to Hympavzi, Pfizer’s anti-tissue ...

Nov 22 (Reuters) - (This Nov. 22 story has been corrected to fix the list price of Pfizer's drug to about $268,000, not $225,000, in paragraph 3) The oral drug, branded as Attruby, was approved to ...

Pfizer PFE announced that the European Commission (“EC”) has granted marketing authorization for Hympavzi (marstacimab) to treat certain hemophilia patients. With this nod, the once-weekly ...

FDA approves BridgeBio's Attruby for ... Also Read: BridgeBio Pharma’s Acoramidis Shows Competitive Edge Against Pfizer’s Tafamidisa In Lucrative But Competitive ATTR-CM Market Attruby is ...

Canalevia ®-CA1 is the first and only treatment for chemotherapy-induced diarrhea (CID) in dogs to receive any type of approval from the FDA By prescription only, Canalevia-CA1 is a canine-specific ...

The study achieved its primary endpoint — treatment with the drug ... Pfizer have lost 13.4% against the industry’s 3.1% growth. The latest decision marks the second EC approval for Pfizer this year ...